[{"id":"6accad76-76f1-4451-99f2-1a7ef5af528e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03344536","created_at":"2021-01-18T16:31:01.100Z","updated_at":"2024-07-02T16:35:59.970Z","phase":"Phase 1/2","brief_title":"A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT03344536","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR • FGFR • CCND1 • FGF3","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 negative • CCND1 amplification • PGR positive • FGF3 amplification • FGFR amplification","tags":["HER-2 • ER • PGR • FGFR • CCND1 • FGF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 negative • CCND1 amplification • PGR positive • FGF3 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • zoligratinib (Debio 1347)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/10/2017","start_date":" 11/10/2017","primary_txt":" Primary completion: 08/12/2021","primary_completion_date":" 08/12/2021","study_txt":" Completion: 08/12/2021","study_completion_date":" 08/12/2021","last_update_posted":"2022-11-24"}]